International University of Health and Welfare Graduate School of Medicine, Japan.
Division of Nephrology, Kouhou-kai Takagi Hospital, Japan.
Intern Med. 2023 Apr 15;62(8):1117-1121. doi: 10.2169/internalmedicine.0040-22. Epub 2022 Sep 13.
Objective We analyzed adverse events retrospectively during a three-year follow-up of patients undergoing hemodialysis at the dialysis center of our general hospital that can treat comprehensive diseases and conducted an exploratory study focusing on the risk factors that determine the prognosis of hemodialysis patients. Methods A total of 132 hemodialysis patients at our dialysis center as of June 2017 were included in the study. Data on event incidence, including death and various clinical indicators, were collected in the electronic medical record for three years until June 2020. Results Between June 2017 and June 2020, 33 of the 132 patients died. The mortality group had a lower body mass index (BMI) and a longer duration of hemodialysis already carried out with more preexisting upper gastrointestinal (GI) bleeding, infections, ischemic heart disease (IHD), and malignancy than the survival group. Furthermore, the mortality group took more warfarin, aspirin, proton pump inhibitors and less H blockers than the survival group. Occurrence of upper or lower GI bleeding was similar between the mortality and survival groups. In a univariate analysis for mortality, the odds ratio was significantly higher for a low BMI (<18), long duration of hemodialysis, history of upper GI bleeding, and presence of IHD. Multivariable-adjusted odds ratios for mortality were significantly higher for cases with a history of upper GI bleeding and BMI <18. Conclusion A history of upper GI bleeding and low BMI may be poor prognostic factors of hemodialysis patients. Careful management of upper GI bleeding and a low BMI are required during the initiation of hemodialysis.
我们对在我院综合疾病透析中心接受血液透析治疗的患者进行了为期三年的随访,回顾性分析了不良事件,并进行了一项探索性研究,重点探讨了决定血液透析患者预后的危险因素。
本研究纳入了截至 2017 年 6 月在我院透析中心接受治疗的 132 名血液透析患者。在三年内,我们从电子病历中收集了包括死亡和各种临床指标在内的事件发生率数据,直至 2020 年 6 月。
在 2017 年 6 月至 2020 年 6 月期间,132 名患者中有 33 人死亡。与生存组相比,死亡组的体重指数(BMI)较低,血液透析时间较长,且存在更多的上消化道(GI)出血、感染、缺血性心脏病(IHD)和恶性肿瘤病史。此外,与生存组相比,死亡组使用华法林、阿司匹林、质子泵抑制剂更多,而使用 H2 受体阻滞剂更少。上或下 GI 出血的发生率在死亡组和生存组之间相似。在对死亡率进行单因素分析时,BMI<18、血液透析时间长、上 GI 出血病史和 IHD 的比值比显著更高。多变量调整后的死亡率比值比在上 GI 出血病史和 BMI<18 的情况下显著更高。
上消化道出血史和低 BMI 可能是血液透析患者的不良预后因素。在开始血液透析时,需要仔细管理上消化道出血和低 BMI。